Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects

Since sodium stibogluconate (SSG) inhibited phosphatases including SHP-1 and augmented anti-tumor actions of IFN-α2b in vitro and in mice, two Phase I trials of SSG/IFN-α2b combination were undertaken to evaluate safety and target inhibition. Escalating doses of SSG (200-1200 mg/m(2)) and fixed dose...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Yi, Taolin, Elson, Paul, Mitsuhashi, Masato, Jacobs, Barbara, Hollovary, Emese, Budd, G. Thomas, Spiro, Timothy, Triozzi, Pierre, Borden, Ernest C.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2011
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3282074/
https://ncbi.nlm.nih.gov/pubmed/22201704
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires